RUTHERFORD, N.J., March 26, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, reported financial results for the 2013 fiscal year and for the fourth quarter ended December 31, 2013. Revenue for the fourth quarter was $1.9 million, an increase of 72%, compared to 2012 fourth quarter revenue of $1.1 million. Full year 2013 revenue was $6.6 million, an increase of 54%, compared to full-year 2012 revenue of $4.3 million. During 2013, 10,771 tests were reported to physicians, pathologists, cancer centers and biotech and pharma customers, up 63% from 6,610 tests during 2012.
Help employers find you! Check out all the jobs and post your resume.
